News

Exclusive to Roswell Park, ‘Armored CAR’ Clinical Trial Targets CD19+ Hematologic Malignancies

A phase 1 clinical trial underway exclusively at Roswell Park Comprehensive Cancer Center will evaluate a novel chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory hematologic malignancies whose tumor ...

Video

Roswell Park Experts Provide Nerve Surgery for Pain Relief, Muscle Restoration

Lindsay Lipinski, MD, FAANS, FACS, walks through three different types of surgeries offered at Roswell Park Comprehensive Cancer Center for patients experience nerve pain or loss of nerve function, whether from cancer treatment or other health complications.

Video

Roswell Park Provides Support, Clinical Trials for Young Adult Sarcoma Patients

As a member of the Sunshine Consortium, Roswell Park Comprehensive Cancer Center has access to, and is developing, clinical trials for young adult patients and their particular needs.

News

FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park.

The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center.

News

Roswell Park Ranked by Forbes Among America’s Best Employers for Women 2024

Roswell Park Comprehensive Cancer Center made its debut on the Forbes list of America’s Best Employers for Women 2024, ranking in the top one-quarter among the 600 organizations included.

News

Next Generation Armored Car T-Cell Therapy Trial Now Open

This Phase I/II trial will test the effectiveness, safety, side effects, and best dose of CD19-targeted Chimeric Antigen Receptor (CAR) modified T cells genetically engineered to secrete interleukin 12 (IL-12) in patients with hematologic B-cell malignancies.